healthcare · late-filing · committee-conflict
Rep. Richard Allen Sells Abbott Labs on Earnings Day, Misses Filing Deadline
The Georgia Republican shed up to $50,000 in Abbott stock just as corporate insiders began buying.
2026-06-11 — Richard W. Allen · ABT
Key facts
- Rep. Richard Allen sold between $15,001 and $50,000 of Abbott Laboratories stock on April 16, 2026.
- The trade occurred on the exact day of Abbott's Q1 earnings release and one day before a litigation settlement announcement.
- Allen disclosed the trade 50 days after execution, missing the 45-day STOCK Act reporting deadline by 5 days.
- Abbott's stock has fallen 7.40% since the sale, though corporate insiders bought shares shortly after Allen sold.
Rep. Richard W. Allen (R-Ga.) closed out a long-held position in healthcare giant Abbott Laboratories (NYSE: ABT) on the exact day the company reported its quarterly earnings. The transaction, valued between $15,001 and $50,000, occurred on April 16, 2026, but was not publicly disclosed until June 5, 2026—fifty days later, missing the federal filing deadline.
The sale was part of a larger cluster of activity; Allen executed six other trades within a 24-hour window, including transactions in Procter & Gamble and S&P Global. While the multi-asset batch suggests routine portfolio rebalancing, the timing of the Abbott trade is notable. On the morning of the trade, Abbott published its first-quarter financial results. The following day, the company disclosed a proposed settlement regarding consolidated infant formula shareholder derivative lawsuits.
Allen’s legislative responsibilities intersect directly with Abbott's business. He serves on the House Committee on Energy and Commerce, which holds direct legislative and oversight jurisdiction over the Food and Drug Administration (FDA)—the primary regulator of Abbott’s medical devices and nutritional products. He also chairs the Subcommittee on Health, Employment, Labor, and Pensions under the Committee on Education and the Workforce.
Since Allen's sale, Abbott’s stock has declined by 7.40%, dropping from $96.81 to $89.65. While the congressman avoided this slide, corporate insiders took the opposite view. In the days following the earnings release, Abbott’s Chief Financial Officer Philip P. Boudreau purchased 2,200 shares on the open market, and director Daniel J. Starks bought 10,000 shares.
Under the STOCK Act, members of Congress are required to disclose trades within 45 days, and all transaction values are reported in ranges. Our analysis scored the trade's overall signal strength at a modest 40 out of 100, reflecting the mixed signals between Allen's exit and the subsequent insider buying.
For now, the congressman’s timing looks sharp, even if his paperwork was late.
Sources
- Abbott Q1 2026 Earnings 8-K — SEC EDGAR
- Abbott Shareholder Derivative Lawsuit Settlement 8-K — SEC EDGAR
- Abbott CFO Philip P. Boudreau Form 4 — SEC EDGAR
- Abbott Director Daniel J. Starks Form 4 — SEC EDGAR